Abstract
Cell therapy is a major discipline of regenerative medicine that has been continually growing over the last two decades. The aging of the population necessitates discovery of therapeutic innovations to combat debilitating disorders, such as stroke. Menstrual blood and Sertoli cells are two gender-specific sources of viable transplantable cells for stroke therapy. The use of autologous cells for the subacute phase of stroke offers practical clinical application. Menstrual blood cells are readily available, display proliferative capacity, pluripotency and angiogenic features, and, following transplantation in stroke models, have the ability to migrate to the infarct site, regulate the inflammatory response, secrete neurotrophic factors, and have the possibility to differentiate into neural lineage. Similarly, the testis-derived Sertoli cells secrete many growth and trophic factors, are highly immunosuppressive, and exert neuroprotective effects in animal models of neurological disorders. We highlight the practicality of experimental and clinical application of menstrual blood cells and Sertoli cells to treat stroke, from cell isolation and cryopreservation to administration.
Keywords: Menstrual blood, Sertoli cells, autologous, ischemic stroke, regenerative.
CNS & Neurological Disorders - Drug Targets
Title:The Battle of the Sexes for Stroke Therapy: Female- Versus Male-Derived Stem Cells
Volume: 12 Issue: 3
Author(s): Yuji Kaneko, Mibel M. Pabon, Travis Dailey, Nathan L. Weinbren, Jessica Rizzi, Cyrus Tamboli, Julianne Vasconcellos, Nicole Kuzmin-Nichols, Paul R. Sanberg, David J. Eve, Naoki Tajiri and Cesar V. Borlongan
Affiliation:
Keywords: Menstrual blood, Sertoli cells, autologous, ischemic stroke, regenerative.
Abstract: Cell therapy is a major discipline of regenerative medicine that has been continually growing over the last two decades. The aging of the population necessitates discovery of therapeutic innovations to combat debilitating disorders, such as stroke. Menstrual blood and Sertoli cells are two gender-specific sources of viable transplantable cells for stroke therapy. The use of autologous cells for the subacute phase of stroke offers practical clinical application. Menstrual blood cells are readily available, display proliferative capacity, pluripotency and angiogenic features, and, following transplantation in stroke models, have the ability to migrate to the infarct site, regulate the inflammatory response, secrete neurotrophic factors, and have the possibility to differentiate into neural lineage. Similarly, the testis-derived Sertoli cells secrete many growth and trophic factors, are highly immunosuppressive, and exert neuroprotective effects in animal models of neurological disorders. We highlight the practicality of experimental and clinical application of menstrual blood cells and Sertoli cells to treat stroke, from cell isolation and cryopreservation to administration.
Export Options
About this article
Cite this article as:
Kaneko Yuji, Pabon Mibel M., Dailey Travis, Weinbren Nathan L., Rizzi Jessica, Tamboli Cyrus, Vasconcellos Julianne, Kuzmin-Nichols Nicole, Sanberg Paul R., Eve David J., Tajiri Naoki and Borlongan Cesar V., The Battle of the Sexes for Stroke Therapy: Female- Versus Male-Derived Stem Cells, CNS & Neurological Disorders - Drug Targets 2013; 12 (3) . https://dx.doi.org/10.2174/1871527311312030013
DOI https://dx.doi.org/10.2174/1871527311312030013 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Steroid Biosynthesis Inhibitors in the Therapy of Hypercortisolism: Theory and Practice
Current Medicinal Chemistry Heme Oxygenase-1 and Iron in Liver Inflammation: A Complex Alliance
Current Drug Targets Pharmacogenetics of Drug Transporters
Current Pharmaceutical Design Potential Molecular Targets of Ampelopsin in Prevention and Treatment of Cancers
Anti-Cancer Agents in Medicinal Chemistry Rock1 & 2 Perform Overlapping and Unique Roles in Angiogenesis and Angiosarcoma Tumor Progression
Current Molecular Medicine Immunotherapy for Prostate Cancer
Current Pharmaceutical Design HIV-1 Vectors: Fulfillment of Expectations, Further Advancements, and Still A Way To Go
Current HIV Research Plasma Steroid Level Measured Using Modern Separation Techniques as Biomarkers in Biological Diagnostics
Current Pharmaceutical Analysis Interactive Effect of Cigarette Smoking and Gene Variants for Predisposing to Cardiovascular Disease
Current Pharmaceutical Design Treatment of Patients with Advanced Thyroid Cancer
Current Biomarkers (Discontinued) Multidrug Transporters as Drug Targets
Current Drug Targets Chemotherapy Resistance in Breast Cancer
Current Cancer Therapy Reviews Alternative Splicing: A Promising Target for Pharmaceutical Inhibition of Pathological Angiogenesis?
Current Pharmaceutical Design Phosphodiesterase Type 5 Inhibitors: Unmet Needs
Current Pharmaceutical Design Recent Developments in Targeting Breast Cancer Stem Cells
Recent Patents on Regenerative Medicine Effectiveness of Resveratrol Against Cardiovascular Disease
Mini-Reviews in Organic Chemistry Pharmacokinetics of CNT-based Drug Delivery Systems
Current Drug Metabolism Melatonin and Male Reproductive Health: Relevance of Darkness and Antioxidant Properties
Current Molecular Medicine Biochemistry and Physiology of Anabolic Androgenic Steroids Doping
Mini-Reviews in Medicinal Chemistry Structural and Functional Organization of miRNAs
Current Pharmacogenomics